Hulskof schreef op 16 augustus 2024 21:38:
Genentech to shut down cancer immunology research department amid broader R&D rethink
Genentech will close its cancer immunology research department, and unit head and renowned cell biologist Ira Mellman, who has been with the company for 17 years, will depart in the coming months.
The company’s cancer immunology research function will be merged with molecular oncology research, which is currently led by Frederic de Sauvage, to form one single cancer research body within Genentech Research and Early Development (gRED), a spokesperson for the Roche subsidiary confirmed to Fierce Biotech.
“This decision was based on our on-the-ground assessment of how best to seize current scientific opportunities in the field, rather than on any Roche-wide decisions about cancer immunology,” the Genentech spokesperson said. “We continue to believe cancer immunology is an important part of our oncology programs.”
www.fiercebiotech.com/biotech/genente...Wat betekent dit voor Affimed???